The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the US and streamlined market standards which enable listed companies to provide a strong baseline of transparency to inform and engage with US investors.
To be eligible, companies must be current in their reporting, meet a minimum bid price test and undergo an annual verification and management certification process.
As a verified market with efficient access to US investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Artelo Biosciences is dedicated to the development and commercialization of proprietary endocannabinoid-modulating therapeutics designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation.
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Bio-Thera and STADA expand biosimilars partnership to include tocilizumab
Shilpa Medicare secures approval for NAFLD therapy NorUDCA in India
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
Seragon launches Enlivien sleep and longevity optimiser
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Fosun Pharma agrees XH-S004 overseas licensing deal
Novartis reports positive Phase III results for ianalumab in Sjögren's disease